Quick Takeaways
- GMS Ventures & Investments filed SCHEDULE 13D/A for Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share (OTLK).
- Disclosed ownership: 50%.
- Date of event: 27 May 2025.
GMS Ventures & Investments - 27 May 2025 SCHEDULE 13D/A Report for Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share (OTLK)
- Filing Manager
- GMS Ventures & Investments
- Reporting Manager
- GMS VENTURES & INVESTMENTS
- Symbol
- OTLK
- Shares outstanding
- 57,735,445 shares
- Disclosed Ownership
- 29,040,929 shares
- Ownership
- 50%
- Form type
- SCHEDULE 13D/A
- Filing time
- 28 May 2025, 17:24:49 UTC
- Date of event
- 27 May 2025
- Previous filing
- 12 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GMS Ventures & Investments disclosed 50% ownership in Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share (OTLK) on 27 May 2025."
What Changed
- Previous schedule filing date: 12 Mar 2025.
- Current filing was accepted on 28 May 2025, 17:24.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| GMS VENTURES & INVESTMENTS | 50% | 29,040,929 | 0 | 29,040,929 | /s/ Lawrence A. Kenyon | Lawrence A. Kenyon/Attorney-in-Fact | 0001804598 |
| SUKHTIAN GHIATH M. | 50% | 29,040,929 | 0 | 29,040,929 | /s/ Lawrence A. Kenyon | Lawrence A. Kenyon/Attorney-in-Fact | 0001717441 |